

An evaluation of improving dialysis adequacy in large haemodialysis patients: the double dialyser study

Submission date
19/09/2007

Recruitment status
No longer recruiting

☐ Prospectively registered

☐ Protocol

Registration date
27/09/2007

Overall study status
Completed

☐ Statistical analysis plan

☒ Results

Last Edited
05/08/2021

Condition category
Urological and Genital Diseases

☐ Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Braden Manns

Contact details

Foothills Medical Center

1403 -29th St NW

Calgary

Canada

T2N 2T9

+1 403 944 2595

Braden.Manns@calgaryhealthregion.ca

Additional identifiers

Protocol serial number

15603

Study information

Scientific Title

An evaluation of improving dialysis adequacy in large haemodialysis patients: the double dialyser study

Study objectives

Health related quality of life for patients treated with a strategy to increase dialysis adequacy will be similar to health related quality of life when treated with standard dialysis.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from the Conjoint Medical Ethics Board of the University of Calgary on the 7th December 2000 (ref: 15603).

Study design

Randomised, controlled, cross-over study

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Kidney failure/haemodialysis

Interventions

All patients were treated for 4 weeks with "4 hours of haemodialysis" three times per week for one month (the run-in period). Then all patients were randomised to receive each of the four noted treatments (below), for six weeks each, in a random order. There was no wash out period between each of the four treatment periods. The intention was that all patients would receive each of the four treatments. Total study time was 24 weeks, plus the 4 week run-in.

1. Standard haemodialysis: four hours of haemodialysis three times per week - haemodialysis was undertaken using a high flux, high efficiency polysulfone dialyser (i.e., F80A dialyser [Fresenius, Inc, Walnut Creek, CA] or equivalent), with a blood flow of 350 - 400 ml/min and a dialysate flow of 500 ml/min
2. Increased dialysate flow: patients received standard dialysis for four hours three times per week but the dialysate flow rate was 800 ml/min rather than 500 ml/min
3. Increased dialysis time: haemodialysis for 4.5 hours, three times per week
4. Double dialyser: patients received haemodialysis for four hours three times per week with two F80A dialysers connected by a Y-connector in a parallel configuration during each run using the method described by Powers et al. Dialysate flow was 800 ml/min

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

'End-Stage Renal Disease (ESRD) symptoms' domain of the Kidney Disease Quality of Life Short Form (KDQOL-SF) measured at the end of each 6-week treatment session.

Key secondary outcome(s)

1. Health Utility Index mark 2 (HUI 2) utility score, evaluated during the last week of the treatment (i.e. during week 6 of each treatment period)
2. Exploratory measures of Health-Related Quality Of Life (HRQOL): other domains of the Kidney Disease Quality of Life (KDQOL) and 36-item Short Form health survey (SF-36), evaluated during the last week of the treatment (i.e. during week 6 of each treatment period)

Completion date

01/07/2004

Eligibility**Key inclusion criteria**

1. Patients on a stable regimen of haemodialysis greater than or equal to 3 months
2. Dry weight greater than or equal to 80 kg
3. Kt/V less than 1.2 on two occasions in the previous 6 months or requirement for greater than 12 hours of haemodialysis per week because of a history of inadequate dialysis
4. Blood flow rate greater than 350 ml/min through a well functioning access
5. Aged greater than 18, both sexes

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Total final enrolment

18

Key exclusion criteria

1. Scheduled renal transplant in the next 6 months
2. Contraindication to intradialytic anticoagulation
3. Requirement for greater than 4.5 hours of haemodialysis three times per week for the purpose of volume removal due to excessive interdialytic weight gains or intradialytic hypotension/cramping
4. Failure to provide informed consent

Date of first enrolment

01/07/2001

Date of final enrolment

01/07/2004

Locations

Countries of recruitment

Canada

Study participating centre

Foothills Medical Center

Calgary

Canada

T2N 2T9

Sponsor information

Organisation

Kidney Foundation of Canada (Canada)

ROR

<https://ror.org/019a0gk53>

Funder(s)

Funder type

Research organisation

Funder Name

Kidney Foundation of Canada (Canada)

Alternative Name(s)

La Fondation canadienne du rein, The Kidney Foundation of Canada, Kidney Foundation, kidneycanada, KFOC

Funding Body Type

Private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location

Canada

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		19/07/2009	05/08/2021	Yes	No